Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUC-MSCs for heart failure with reduced ejection fraction
ChiCTR2000040778Phase 2Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Dec 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of human umbilical cord mesenchymal stem cells in heart failure with reduced ejection fraction (HFrEF) (4 arms), sponsored by Shanghai East Hospital. Primary endpoint: Cardiac function evaluated by echocardiography. Started Dec 2020; status: recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR2000040778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040778.